FDA OK's Lilly's Cyramza in colon cancer

 
• By Donna Young

Lilly's Cyramza (ramucirumab) has won another US indication: metastatic colorectal cancer (mCRC).

More from Alimentary/Metabolic

More from Therapy Areas